Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous …
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
This week | ||
Older | ||
IInsider Monkey | ||
 Assessing Nanobiotix (ENXTPA:NANO) Valuation After Strong Recent Share Price Momentum What recent performance says about Nanobiotix Nanobiotix (ENXTPA:NANO) has caught investors attention after a recent one-day return of 2.2% moved alongside a one-month gain of 6.1% and a past three-month return of 51.2%. Those moves come against a backdrop of annual revenue of €32.593 million, a reported net loss of €23.961 million and a market value of about €1.36b. This highlights a clinical stage biotech profile with ongoing development spend. See our latest analysis for Nanobiotix. The... | ||
 Nanobiotix H2 Earnings Call Highlights Nanobiotix (NASDAQ:NBTX) executives said the company made “a very rich” set of operational and financial moves in 2025, highlighting progress in its Johnson & Johnson collaboration around NBTXR3/JNJ-1900, a continued pivot toward its Curadigm nanoprimer platform, and an extended cash runway into | ||
Sector Update: Health Care Stocks Gain Late Afternoon Health care stocks rose late Wednesday afternoon, with the NYSE Health Care Index adding 1% and the | MMT Newswires | |
Nanobiotix (ENXTPA:NANO): Assessing Valuation After a Powerful Multi‑Month Share Price Surge Market context and recent performance Nanobiotix (ENXTPA:NANO) has quietly turned into one of the stronger movers in European biotech this year, with the share price up nearly 5% year to date and more than doubling over the past 3 months. See our latest analysis for Nanobiotix. With the share price now at $18.28 and a powerful 90 day share price return of around 132 percent, on top of a roughly 491 percent 1 year total shareholder return, momentum appears to be building rather than cooling... | ||
 Biotech Stock Nanobiotix (NBTX) Is Up 660% This Year -- Here's Why the Rally Could Continue It has grown wildly, and it could keep growing. | ||
Nanobiotix (ENXTPA:NANO): Evaluating Valuation After $71 Million Royalty Deal Expands Growth Prospects Nanobiotix (ENXTPA:NANO) has drawn investor attention after announcing a royalty-based financing agreement with HealthCare Royalty, unlocking up to $71 million in capital. This move strengthens its financial footing and supports the advancement of future nanotherapeutic products. See our latest analysis for Nanobiotix. Momentum has shifted dramatically for Nanobiotix, with the share price surging 502.86% year-to-date and an impressive 173.16% gain over the last 90 days. This follows the... | ||
Why Nanobiotix (ENXTPA:NANO) Is Up 5.9% After Securing $71M in Non-Dilutive Financing and What’s Next Nanobiotix announced it has secured a royalty-based financing agreement with HealthCare Royalty, providing up to US$71 million in non-dilutive capital and up to a US$124 million repayment cap if completed by the end of 2030. This financing move strengthens Nanobiotix's financial position and supports the advancement of its nanotherapeutic platforms without diluting existing shareholders. We'll explore how this injection of non-dilutive capital shapes Nanobiotix’s investment narrative and... | ||